Targeting the DNA damage response through TBL1X in mantle cell lymphoma

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with poor prognosis.
• Genomic instability is a hallmark of MCL, necessitating novel therapeutic strategies.
• Transducin β-like protein 1 X-linked (TBL1X) is implicated in cancer but its role in MCL is unknown.

Purpose of the Study:

• To investigate the role of TBL1X in MCL pathogenesis.
• To evaluate TBL1X as a therapeutic target in MCL.
• To assess the efficacy of targeting TBL1X alone and in combination with other agents.

Main Methods:

• Assessed TBL1X expression in MCL cells.
• Utilized genetic knockdown of TBL1X and tegavivint treatment in vitro and in vivo.
• Investigated the effect of TBL1X inhibition on MCL oncogenic drivers (cyclin D1, RAD51).
• Evaluated combination therapy with tegavivint and talazoparib.

Main Results:

• MCL cells exhibit high TBL1X expression compared to normal B cells.
• TBL1X knockdown and tegavivint treatment induced MCL cell death and DNA damage.
• Targeting TBL1X destabilized key oncogenic drivers, causing cell cycle arrest.
• Combination of tegavivint and talazoparib demonstrated synergistic cell death and prolonged survival in vivo.

Conclusions:

• TBL1X plays a critical role in maintaining genomic stability in MCL.
• Targeting TBL1X represents a novel and effective therapeutic strategy for MCL.
• Combination therapy holds significant potential for improving outcomes in MCL patients.